A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES)

Tamas Pinter; Zandra Klippel; Alvydas Cesas; Adina Croitoru; Jochen Decaestecker; Peter Gibbs; Yevhen Hotko; Jacek Jassem; Galina Kurteva; Jan Novotny; Seamus O'Reilly; Tomas Salek; Maureen Reiner; Phuong Khanh Morrow; Mi Rim Choi; Sadie Whittaker; Charles Blanke

Journal article

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES)

Tamas Pinter, Zandra Klippel, Alvydas Cesas, Adina Croitoru, Jochen Decaestecker, Peter Gibbs, Yevhen Hotko, Jacek Jassem, Galina Kurteva, Jan Novotny, Seamus O'Reilly, Tomas Salek, Maureen Reiner, Phuong Khanh Morrow, Mi Rim Choi, Sadie Whittaker, Charles Blanke

Clinical Colorectal Cancer | CIG MEDIA GROUP, LP | Published : 2017

DOI: 10.1016/j.clcc.2016.08.008

University of Melbourne Researchers

Peter Gibbs Author Surgery - Royal Melbourne Hospital

Grants

Funding Acknowledgements

This work was supported by Amgen Inc. Kathryn Boorer of Amgen Inc and Martha Mutomba (on behalf of Amgen Inc) provided writing assistance. The authors thank Esteban Abella, a former employee of Amgen Inc, and May Mo of Amgen Inc for their involvement in the study design and analysis and interpretation of data. The authors also thank Florian Vogl of Amgen Inc for useful discussions.